Open AccessEffect of Aspirin and Indomethacin on Prostaglandin E2 Synthesis in C6 Glioma Cells
Author(s) -
Hwang ShiuhLin,
Lee KungShing,
Lin ChihLung,
Lieu AnnShung,
Cheng ChiYun,
Loh JoonKhim,
Hwang YanFen,
Su YuFeng,
Howng ShenLong
Publication year - 2004
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/s1607-551x(09)70076-2
Subject(s) - aspirin , medicine , prostaglandin e2 , pharmacology , glioma , prostaglandin , immunosuppression , cancer research
Prostaglandin E2 (PGE2) plays an important role in immunosuppression and tumor growth. PGE2 inhibitors such as aspirin and indomethacin suppress experimental tumor growth. Little is known of the relationship between PGE2 synthesis in brain tumors and the dose of aspirin or indomethacin. The present study was undertaken to evaluate the effect of different doses of aspirin and indomethacin on PGE2 synthesis in C6 glioma cells. C6 glioma cells were incubated with different concentrations (2, 4, and 8 μM) of aspirin and indomethacin for 1, 2, 4, 6, 8, 12, and 24 hours. Intracellular PGE2 concentration was measured by enzyme immunoassay. Each concentration of aspirin and indomethacin effectively inhibited PGE2 synthesis. Concentrations of 2, 4, and 8 μM of aspirin significantly inhibited PGE2 production at 6, 4, and 1 hours, respectively, and the inhibition persisted for more than 24 hours ( p < 0.05). Concentrations of 2 and 4 μM of indomethacin were effective at 4 and 2 hours ( p < 0.05), respectively. However, inhibition was not observed beyond 12 hours ( p > 0.05). Indomethacin 8 μM was effective at 1 hour and the inhibition persisted beyond 24 hours ( p < 0.05). Our study demonstrates that aspirin and indomethacin inhibit PGE2 synthesis in C6 glioma cells and that low‐dose aspirin is as effective as high‐dose aspirin. This study may encourage future clinical use of low‐dose aspirin in the prevention or treatment of brain tumors.